Shanghai Jenomed Biotech Co., Ltd. was founded in September 2015 by overseas returnee scientists and has been a resident-company at Zhangjiang Pharma Valley, a National Bio-Pharmaceutical incubator in Shanghai, since its inception. The company's founders and core team members have many years of R&D and business management experience in the field of bio-pharma at home and abroad. They have filed 12 domestic and foreign patent applications, of which 2 Chinese invention patents have been granted. The company focuses on R&D activities involved in proprietary identification of neoantigens from CTCs, enriched from cancer patient’s plasma non-invasively, and subsequent preparation of patient’s specific personalized cancer vaccines (PCVs). It has established a proprietary and leading-edge animal mammary gland bioreactor platform and >13 complex proteins including some difficult to express proteins, such as ion channels, GPCRs, and other membrane proteins, have been highly expressed in the milk (>1mg/ml). Molecular and cell biology laboratory of the company is equipped with state of art instruments and strived to provide specialized biopharmaceutical and medical products and services. Its parent company, Nanjing Jenomed Biotech Co., Ltd., a Sino-Foreign joint venture, was incorporated in Nanjing in 2012. The parent company is focused on establishing animal mammary gland bioreactor platform to produce much-needed pharmaceutically important proteins, as well as providing other biopharmaceutical and medical products and services. Both companies aim to become bio-pharmaceutical industry’s leading enterprise in next 5-7 years.